EUVIMEDEUVIMED entdecken
Crossref

Interim Analysis of the TIGERCAMP Trial Evaluating Cellular, Acellular, and Matrix-Like Products (CAMPS) in Diabetic Foot Ulcers

Sasha Frade, Brianna Tramelli, Zwelithini Tunyiswa, Dereck Shi, Emily Cook, Thomas Serena

Chronic Wound Care Management and Research · 29.07.2026 · 1 (1)

DOI: 10.67702/bwji2325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chronic Wound Care Management and Research, erschienen am 29.07.2026. Verfasst von Sasha Frade und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic wounds, including diabetic foot ulcers (DFUs), often fail to achieve closure under standard of care (SOC). Cellular, acellular, and matrix-like products (CAMPs) have emerged as advanced wound care therapies intended for use in wounds that fail to respond adequately to SOC. The TIGERCAMP trial was designed as a modified platform study to evaluate multiple CAMPs in the management of DFUs.

Methods

TIGERCAMP is a multicenter, prospective, randomized controlled platform trial comparing SOC alone to SOC plus multiple CAMPs in adults (≥21 years) with nonhealing DFUs. SOC included debridement, infection control, moisture balance, and offloading. The primary endpoint was confirmed complete wound closure at 12 weeks following treatment initiation. Secondary endpoints include time to closure, percent wound area reduction (PAR), pain, adverse events, and number of graft applications. This report presents a pre-specified interim analysis using descriptive summaries and Bayesian statistical methods to evaluate clinical outcomes. The product evaluated in this interim analysis is a full-thickness placental membrane allograft (FT; caregraFT™, Tiger Wound Care Medical, LLC, Conshohocken, PA, US).

Results

A total of 168 participants were screened, of whom 71 were included in the interim analysis. Bayesian estimates of complete wound closure at 12 weeks directionally favored FT+SOC relative to SOC alone, with numerically higher posterior estimates observed in the FT+SOC arm. The posterior probability of wound closure under SOC alone was 27.7% (95% credible interval: 12.6% - 43.8%), while higher posterior estimates were observed in the FT+SOC cohort. PAR estimates were also directionally greater among FT+SOC-treated participants compared with SOC alone.

Conclusions

Interim findings from the TIGERCAMP platform trial suggest that FT applied as an adjunct to SOC demonstrated directionally favorable wound closure and PAR outcomes compared with SOC alone. While dataset is exploratory and interim in nature, these findings support continued evaluation of FT within the ongoing TIGERCAMP trial.

Zitieren

APA

Frade, S., Tramelli, B., Tunyiswa, Z., Shi, D., Cook, E., & Serena, T. (2026). Interim Analysis of the TIGERCAMP Trial Evaluating Cellular, Acellular, and Matrix-Like Products (CAMPS) in Diabetic Foot Ulcers. Chronic Wound Care Management and Research, 1(1). https://doi.org/10.67702/bwji2325

Vancouver

Frade S, Tramelli B, Tunyiswa Z, Shi D, Cook E, Serena T. Interim Analysis of the TIGERCAMP Trial Evaluating Cellular, Acellular, and Matrix-Like Products (CAMPS) in Diabetic Foot Ulcers. Chronic Wound Care Management and Research. 2026;1(1). doi:10.67702/bwji2325

BibTeX
@article{Frade2026,
  author = {Frade, Sasha and Tramelli, Brianna and Tunyiswa, Zwelithini and Shi, Dereck and Cook, Emily and Serena, Thomas},
  title = {Interim Analysis of the TIGERCAMP Trial Evaluating Cellular, Acellular, and Matrix-Like Products (CAMPS) in Diabetic Foot Ulcers},
  journal = {Chronic Wound Care Management and Research},
  year = {2026},
  volume = {1},
  number = {1},
  doi = {10.67702/bwji2325}
}
Kostenlos starten →